drugset / Trial / NCT00568061

Nitric Oxide in Myocardial Infarction Size

NCT00568061

Phase 2 Terminated 29 enrolled Mallinckrodt
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful percutaneous coronary intervention.

Timeline

Start
2006-06
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 80 ppm Inhaled